[quick news] December 20, 2019 nature: heavyweight! It was found that there were stem cell like T cells in the tumor
-
Last Update: 2019-12-20
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Nature: heavyweight! In a new study, researchers from Emory University and other research institutions found that the immune system has established a "front-line battle base" or lymph node like structure in the tumor of some patients with renal cancer and other urinary system cancers Patients with well supported immune cells in tumors are more likely to control cancer growth in their bodies for a longer period of time This finding may guide the treatment decisions of renal cancer patients after surgery Http:// the new method can effectively inactivate the antibiotic resistance gene The research team of the University of California, San Diego recently published a paper in nature communication, saying that they have developed a new gene driving system, pro AG, which can effectively inactivate the antibiotic resistance gene of bacteria Its efficiency is higher than that of CRISPR The system control method is 100 times higher The researchers say Pro Ag technology can be used to treat chronic bacterial infections, such as cystic fibrosis, chronic urinary tract infection, tuberculosis and other diseases Http://news.sciencenet.cn/htmlnews/2019/12/433992.shtm BRICs promote multilateral cooperation in biotechnology in Campinas, Brazil The third BRICs working group meeting on science, technology, innovation, biotechnology and biomedicine was held successfully BRICs cooperation aims to supplement and strengthen existing bilateral and multilateral relations among Member States Among them, biotechnology and biomedicine, including human health and neuroscience, are among the priority areas of cooperation within ICGEB's mandate The meeting of the working group focused on the identification of scientific themes in a transnational form Http://digitalpaper.stdaily.com/http_ / 20 / content_ HTM? Div = - 1 the macroscopic preparation of graphene by plasma by our scientists is considered to be a revolutionary functional / structural material in the future, which has important applications in energy environment, biomedicine, electronic devices, chemical industry and aerospace Professor Xia Weidong, Department of thermal science and energy engineering, College of engineering, University of science and technology of China, worked with his research team and collaborators to propose a new method of "synthesizing graphene by large area uniform thermal plasma generated by magnetic dispersion arc", which broke through the technical bottleneck of thermal plasma process or high energy consumption, or low product uniformity and insufficient production stability, and is expected to achieve large-scale connectivity Continued production Http://digitalpaper.stdaily.com/http_ Div = - 1 rheumatoid arthritis (RA) blockbuster new drug! Rinvoq, an oral inhibitor of Jak1, has been approved by the European Union Its annual sales may reach $2.6 billion Abbvie, an American biopharmaceutical giant, recently announced that the European Commission (EC) has approved rinvoq (uPA acitinib), a Jak1 inhibitor, to be used in the moderate to severe categories with insufficient or intolerant response to one or more modified antirheumatic drugs (DMARD) Treatment of adult patients with rheumatoid arthritis (RA) Currently, rinvoq is on the market in the United States It is not suitable for patients who have not received MTX treatment Rinvoq also marks the second Tim therapy approved by the US FDA this year It is worth mentioning that Albright accelerated rinvoq's review by using a priority review voucher (PRV), reducing the drug review cycle from the regular 10 months to 6 months http://
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.